Lexicon (LXRX) SVP awarded 257,530 RSUs and 386,300 stock options

Rhea-AI Filing Summary

Lexicon Pharmaceuticals, Inc. reported equity awards to senior vice president Lisa DeFrancesco. On February 12, 2026, she received 257,530 restricted stock units, each representing a right to one share of common stock, and 386,300 stock options with a $1.37 exercise price.

The restricted stock units vest in three equal installments on February 28 of each of the three years after the grant year. The stock options vest 25% on the first anniversary of grant, with the remaining portion vesting monthly over the following three years, contingent on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider DeFrancesco Lisa

Role SVP, IR and Corp Comm

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	257,530	$0.00	--
Grant/Award	Stock Option (Right to Buy)	386,300	$0.00	--

Holdings After Transaction: Restricted Stock Units — 257,530 shares (Direct); Stock Option (Right to Buy) — 386,300 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of common stock. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant. Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeFrancesco Lisa

(Last) (First) (Middle)

2445 TECHNOLOGY FOREST BLVD

11TH FLOOR

(Street)

SPRING TX 77381

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEXICON PHARMACEUTICALS, INC. [ LXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, IR and Corp Comm

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/12/2026		A		257,530		(2)	(2)	Common Stock	257,530	$0	257,530	D
Stock Option (Right to Buy)	$1.37	02/12/2026		A		386,300		(3)	02/12/2036	Common Stock	386,300	$0	386,300	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of common stock.

2. Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.

3. Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.

	/s/ Lisa M. DeFrancesco	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did LXRX report for Lisa DeFrancesco?

Lexicon Pharmaceuticals reported equity awards to SVP Lisa DeFrancesco. She received 257,530 restricted stock units and 386,300 stock options on February 12, 2026, as part of her compensation. Both awards vest over multiple years tied to continued service.

How many restricted stock units did the LXRX executive receive?

Lisa DeFrancesco received 257,530 restricted stock units from Lexicon Pharmaceuticals. Each unit represents a contingent right to one share of common stock. The units vest in three equal installments on February 28 in each of the three years following the grant year.

What are the terms of the LXRX stock options granted on February 12, 2026?

Lexicon Pharmaceuticals granted 386,300 stock options with a $1.37 exercise price to Lisa DeFrancesco. Twenty-five percent vest on the first anniversary of grant, with the remainder vesting in equal monthly installments over the next three years of continued service.

Is the LXRX Form 4 transaction a purchase or a grant?

The LXRX Form 4 reflects equity grants, not market purchases. The filing shows an acquisition of restricted stock units and stock options as compensation awards, both recorded with transaction code “A” for grant, award, or other acquisition, at no cash price per unit on the grant date.

What role does the reporting person hold at Lexicon Pharmaceuticals (LXRX)?

The reporting person, Lisa DeFrancesco, serves as an officer at Lexicon Pharmaceuticals. Her title is Senior Vice President, Investor Relations and Corporate Communications. The reported restricted stock units and stock options reflect part of her incentive-based compensation package from the company.

How do the LXRX restricted stock units vest over time?

The LXRX restricted stock units vest in three equal parts. One-third of the 257,530 units vests on February 28 of each of the three years following the grant year, subject to her continued service with Lexicon Pharmaceuticals during the vesting period.